Login / Signup

Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model.

Sumit KumarMark J A SchoonderwoerdJessie S KroonenIlona J de GraafMarjolein SluijterDina RuanoRomán González-PrietoMatty Verlaan-de VriesJasper RipRamon ArensNoel F C C de MirandaLukas J A C HawinkelsThorbald van HallAlfred C O Vertegaal
Published in: Gut (2022)
Our findings indicate that pharmacological inhibition of the SUMO pathway represents a potential strategy to target PDAC via a dual mechanism: inhibiting cancer cell cycle progression and activating anti-tumour immunity by inducing interferon signalling.
Keyphrases
  • cell cycle
  • cell proliferation
  • papillary thyroid
  • signaling pathway
  • squamous cell
  • dendritic cells
  • childhood cancer
  • drug delivery
  • cancer therapy
  • risk assessment